Mounjaro & Zepbound NAION Lawsuits
Manufactured by Eli Lilly and Company, both Mounjaro and Zepbound contain the active ingredient tirzepatide. Tirzepatide is similar to semaglutide, which is used in similar GLP-1 medications like Ozempic, Rybelsus, and Wegovy.
These medications can help patients dealing with type 2 diabetes and obesity. However, some users have reported serious side effects like vision loss and blindness from non-arteritic anterior ischemic optic neuropathy (NAION).
Patients taking tirzepatide, semaglutide, or both are nearly twice as likely to develop NAION than patients on other diabetes medications, according to JAMA Network Open.
To date, over 146 GLP-1 NAION lawsuits have been consolidated in a multidistrict litigation (MDL), which is where similar claims are grouped together and overseen by a single judge to make pretrial proceedings more efficient
If you developed NAION after taking a GLP-1, you may be able to file a Mounjaro or Zepbound NAION lawsuit against the pharmaceutical company that failed to adequately warn you about this risk. Contact our tirzepatide NAION lawyers now.
Get the Help You Deserve
If you developed NAION after using Mounjaro or Zepbound, we may be able to help you pursue compensation for your injuries.
Can Mounjaro & Zepbound Cause NAION?
NAION occurs when there is a sudden loss of blood flow to the optic nerve, resulting in vision loss. GLP-1 medications may cause changes in blood sugar and blood vessel function that some researchers believe can affect circulation to this nerve.
There have been multiple cases of patients who began taking a tirzepatide medication like Mounjaro or Zepbound and developed NAION shortly after.
Several such cases were documented in JAMA Ophthalmology:
- A man in his 60s had been taking 2.5 mg of tirzepatide for a year to manage type 2 diabetes when he woke up with painless vision loss in one eye. He continued taking the medication after his diagnosis, since no association between tirzepatide and NAION had been reported at the time.
- Another man developed sudden, painless vision loss in one eye 4 months after his tirzepatide dosage was increased from 5 mg to 10 mg in order to manage his diabetes. An optometrist observed that his left optic nerve was swollen.
- A woman in her 50s had been taking 10 mg of tirzepatide for 5 months for weight loss when she woke up with painless vision loss in one eye. Her vision worsened over the following weeks, and after her doctor told her to stop taking the medication, the swelling of her optic nerve resolved.
As researchers continue to investigate the link between tirzepatide and NAION, it’s important for patients taking Mounjaro or Zepbound to know the warning signs of this condition and consult their doctor if symptoms occur.
NAION Symptoms from Mounjaro & Zepbound
Using a tirzepatide medication like Mounjaro or Zepbound may cause serious side effects, including NAION. Some patients believe Eli Lilly failed to properly warn them about these risks.
NAION symptoms can come on suddenly and may include:
- Difficulty seeing color or contrast clearly (dyschromatopsia)
- Painless vision loss or blurriness, often noticed upon waking
- Swelling of the optic nerve, which a doctor can detect during an eye exam
- Vision loss limited to one eye, though both eyes can be affected over time
Anyone who experiences sudden vision changes while taking Mounjaro or Zepbound should seek immediate medical attention.
Who Can File a Mounjaro Zepbound NAION Lawsuit?
Anyone who used a GLP-1 and later experienced vision loss or blindness may be able to file a Mounjaro Zepbound NAION lawsuit.
Eligibility for a Mounjaro or Zepbound NAION lawsuit typically involves:
- Proof that you used a tirzepatide drug such as Mounjaro or Zepbound
- Documentation that you suffered serious health issues like non-arteritic anterior ischemic optic neuropathy (NAION)
- Medical records showing you were hospitalized, went to the ER, or needed a follow-up with a specialist for your injury
If you took another GLP-1 medication like Ozempic, Rybelsus, Saxenda, Trulicity, or Wegovy, you may still be eligible to take legal action and pursue compensation for similar side effects.
Call (800) 995-1212 now to see if you may be able to pursue compensation from a Mounjaro or Zepbound NAION lawsuit. It costs nothing to speak with us.
NAION Zepbound Lawsuit Deadline
There’s only a limited amount of time to file a NAION Zepbound lawsuit due to state laws known as statutes of limitations.
The deadline to take legal action varies from state to state, but once it passes in your case, you won’t be able to file a Mounjaro NAION lawsuit for your injuries again.
Contact our team as soon as possible for a free case review, so you don’t miss your chance for justice.
How to File a Zepbound & Mounjaro Vision Loss Lawsuit
At Sokolove Law, our team strives to make filing a Zepbound or Mounjaro lawsuit for vision loss as simple and stress-free as possible.
We’ll handle every step of the legal process if you have a case, so you can focus on your health while we pursue compensation on your behalf.
Our Zepbound and Mounjaro NAION lawyers can:
- Determine your eligibility to take legal action during a free case review
- Gather evidence like medical records and expert testimony to build a strong case
- File your NAION tirzepatide lawsuit before any statutes of limitations or state deadlines
- Negotiate a settlement with the defendant(s)
- Pursue a verdict in court if a settlement is unable to be reached
You shouldn’t have to suffer as a result of a pharmaceutical company’s negligence. By filing a NAION Mounjaro lawsuit against Eli Lilly, you can pursue compensation for your injuries and send a clear message that what you experienced was unacceptable.
Mounjaro Settlements & Verdicts
Mounjaro lawsuits could award compensation in one of two ways:
- Mounjaro settlement: After your lawyers negotiate with the drug manufacturer, they may reach a Mounjaro lawsuit settlement. This agreed upon amount of compensation for your injuries is often awarded before your case goes to trial.
- Mounjaro verdict: If a settlement isn’t reached, your case will proceed to a trial in court. After your lawyer presents your case, a judge or jury will decide on the amount of compensation you may be awarded, though there’s no guarantee of success in trials.
Let us get you the money you deserve. Call (800) 995-1212 now to get started for free.
Mounjaro Lawsuit Updates 2025-2026
Our firm is committed to providing accurate, up-to-date information about lawsuits for side effects potentially caused by the use of Mounjaro.
Recent Mounjaro lawsuit updates include:
- June 2026: A Science Day was held before Judge Marston, who is overseeing the Mounjaro blindness lawsuit. Both sides presented expert medical and scientific evidence about the link between GLP-1 drugs and NAION to help the court evaluate what expert testimony will be admissible at trial.
- May 2026: At least 86 GLP-1 NAION lawsuits are currently pending in the MDL. This number is expected to grow as more patients learn about the potential link between vision loss and GLP-1 medications.
- December 2025: The Judicial Panel on Multidistrict Litigation approved the creation of a new MDL, No. 3163, specifically for NAION and vision loss claims tied to GLP-1 drugs like Mounjaro and Zepbound.
- August 2025: Eli Lilly asked the court to consolidate vision loss lawsuits into a new, separate multidistrict litigation to be heard by the same judge already overseeing the existing GLP-1 MDL.
- July 2025: The first tirzepatide NAION lawsuit brought in federal court against Eli Lilly was filed in the Eastern District of Pennsylvania.
- January 2025: A case series documenting patients who used tirzepatide and later developed NAION was published in JAMA Ophthalmology, adding to growing concern about a potential link between GLP-1 medications and vision loss.
- April 2024: Multiple victims have come forward to join the Mounjaro multidistrict litigation (MDL), with 74 lawsuits pending against pharmaceutical companies like Eli Lilly and Novo Nordisk.
- February 2024: Lawsuits for injuries caused by GLP-1 drugs like Mounjaro, Ozempic, Rybelsus, and Wegovy were officially consolidated into an MDL in the Eastern District of Pennsylvania.
- December 2023: Lawyers representing victims harmed by Mounjaro and other weight loss drugs requested the claims be combined into an MDL, which is similar to a class action lawsuit, to speed up the process of gathering evidence for these cases.
- August 2023: A weight loss drug lawsuit was filed against Eli Lilly and Novo Nordisk after a patient who took both Mounjaro and Ozempic was hospitalized for serious gastrointestinal side effects.
At Sokolove Law, our experienced Mounjaro lawyers will keep you updated every step of the way as your case progresses and we fight on your behalf.
Get Help Filing a NAION Zepbound or Mounjaro Lawsuit
At Sokolove Law, we can help families in all 50 states pursue compensation from a NAION Zepbound or Mounjaro lawsuit.
Our attorneys have the resources and experience necessary to level the playing field against large pharmaceutical companies, and there are no upfront costs or hourly fees to work with our team.
We’ve secured more than $1.6 Billion nationwide for victims of dangerous drugs and medical devices.
Call (800) 995-1212 now or fill out our contact form to get a free, no-obligation case review.
Note: Do not change medications without first consulting your doctor.
All brands are trademarks of their respective companies.
NAION Tirzepatide Lawsuit FAQs
Is there a lawsuit against Mounjaro?
Yes. Multiple patients have filed Mounjaro lawsuits against Eli Lilly, the pharmaceutical company that manufactures this medication.
These lawsuits allege the company failed to warn users about serious side effects caused by Mounjaro, including vision loss caused by non-arteritic anterior ischemic optic neuropathy (NAION).
Get a free case review now to find out if you may be able to pursue compensation from a Mounjaro lawsuit.
Does Mounjaro cause NAION?
The use of Mounjaro may increase a patient’s risk of NAION (non-arteritic anterior ischemic optic neuropathy), according to research published in JAMA Ophthalmology.
Mounjaro contains tirzepatide, a drug in the same GLP-1 class as Ozempic. Researchers believe these medications can affect blood flow to the optic nerve, which may lead to nerve damage and vision loss.
If you experienced vision loss after taking Mounjaro, you may be eligible for compensation from a Mounjaro NAION lawsuit.
Is Mounjaro being recalled?
Despite the growing number of serious side effects being reported, Eli Lilly has not recalled Mounjaro or Zepbound at this time.
Even though Mounjaro has not been recalled, patients who were harmed by this medication may still be able to seek justice by filing a tirzepatide lawsuit.
Call (800) 995-1212 now to see if you may qualify. It costs nothing to speak with us.
How common is NAION with Mounjaro?
NAION is a rare but serious potential side effect reported in patients taking Mounjaro and Zepbound.
While research specifically isolating tirzepatide's NAION risk is still limited, a study in JAMA Network Open found that patients taking tirzepatide, semaglutide, or both were nearly twice as likely to develop NAION compared to those on other diabetes medications.
How much does it cost to file a Mounjaro lawsuit?
There are no hourly fees or out-of-pocket costs to file a Mounjaro lawsuit with Sokolove Law.
We work on a contingency-fee basis, which means our attorneys only get paid if we successfully secure compensation for you.
Is there a class action lawsuit for Mounjaro?
Claims involving Mounjaro have been consolidated into two separate multidistrict litigation (MDL) proceedings, which are similar to a Mounjaro class action lawsuit.
There are currently 146 lawsuits involving vision loss or NAION lawsuits pending in MDL No. 3163 and 3,848 GLP-1 lawsuits for gastrointestinal issues pending in MDL No. 3094.
Multiple GLP-1 drugs are involved in the MDLs, including Ozempic, Wegovy, and Rybelsus. The lawsuits allege pharmaceutical companies failed to adequately warn patients about serious side effects linked to these medications.
Call (800) 995-1212 now to see if we can fight for justice on your behalf. There’s still time to join the Mounjaro lawsuit.
What is the Zepbound lawsuit about?
Zepbound lawsuits accuse Eli Lilly of failing to warn users about the risks potentially associated with taking this weight loss medication, like a serious eye condition called non-arteritic anterior ischemic optic neuropathy (NAION).
If you experienced vision loss or blindness after using Zepbound, you may be eligible to file a Zepbound lawsuit.
Contact us now to find out more about your legal options during a free case review.
Is Mounjaro the same as Zepbound?
While Mounjaro and Zepbound both contain the active ingredient tirzepatide, the two drugs are approved for different uses:
- Mounjaro is intended to manage glucose levels in adults with diabetes
- Zepbound is used to help adults with weight loss
Unfortunately, patients claim these tirzepatide weight loss drugs can cause serious gastrointestinal issues like stomach paralysis and bowel obstructions.
Can Mounjaro cause stomach paralysis?
Yes, possibly. Lawsuits against Mounjaro’s manufacturer allege the drug can cause stomach paralysis (gastroparesis), bowel or intestinal obstructions, and other intestinal issues.
Are Mounjaro and Trulicity the same thing?
No. Both Mounjaro and Trulicity are made by Eli Lilly, but they are different medications with different active ingredients.
Mounjaro contains tirzepatide, a dual GIP/GLP-1 receptor agonist approved to treat type 2 diabetes and widely used for weight loss. Trulicity contains dulaglutide, an older GLP-1 receptor agonist also approved for type 2 diabetes.
While both work by targeting GLP-1 receptors to help regulate blood sugar, tirzepatide also targets a second receptor (GIP) that dulaglutide does not, making them distinct drugs with different mechanisms, dosing, and side effect profiles.
What are some Mounjaro tirzepatide side effects?
Patients have reported many Mounjaro tirzepatide side effects, including:
- Vision loss caused by non-arteritic anterior ischemic optic neuropathy (NAION)
- Stomach paralysis (gastroparesis)
- Bowel or intestinal obstructions
- Chronic vomiting
- Deep vein thrombosis (DVT)
- Esophageal injury
- Ileus (intestinal inability to contract and pass waste)
- Intraoperative pulmonary aspiration
- Malnutrition-related disorders
- Pancreatic cancer
If you suffered serious side effects after using Mounjaro or Zepbound, contact Sokolove Law now to learn more about your legal options.
